Instil Bio competitors

Accomplished pharma/biotech business leader with over twenty years of professional experience managing and building culture in both private and publicly traded companies. Proven leader with the vision and management skills necessary to lead a successful organization. Extensive experience in mergers and acquisitions as well as post-merger integration. Significant experience building relationships with investors and analysts and presenting to the investor community. Served as advisor to and member of private and public company boards. Areas of Leadership Expertise: ▪ Product Development ▪ New Product Launches ▪ Mergers & Acquisitions ▪ Post-merger Integration ▪ Executive Team Building ▪ Budgeting/Financial Planning ▪ Business Development ▪ Corporate Partners & JVs ▪ Corporate Governance ▪ Investor Relations

Adrian (Ad) Rawcliffe is a Chief Executive Officer at Adaptimmune, Senior VP:Worldwide Bus Dev at GSK, and Board Member at WaVe Life Sciences Pte Ltd and is based in Philadelphia, Pennsylvania. He has worked as Chartered Accountant at Pricewaterhouse Coopers (PwC), President/Managing Partner at Sr One, and Chief Financial Officer at Adaptimmune Therapeutics Plc. Adrian (Ad) studied at Durham University between 1990 and 1993 and Masters of Awkward.

Dr. Lara S. Sullivan is the Chief Executive Officer of Pyxis Oncology. Prior to joining Pyxis, Lara was Founder and President of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical stage biopharmaceutical company spun-out from Pfizer. While at Pfizer, Lara led strategy, competitive intelligence and portfolio operations for the company’s early-stage R&D pipeline. Prior to joining Pfizer, Lara was an associate partner at McKinsey & Company, where she specialized in biopharmaceutical R&D productivity and efficiency. Lara also served as a principal at Paul Capital Partners, where she led due diligence for healthcare investments, and earlier in her career worked in healthcare equity research and healthcare municipal finance at Credit Suisse First Boston. Lara holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.

Liz Homans has served as Chief Executive Officer and member of the board of directors since August 2020. From September 2018 to August 2020, she served as President and the operational lead as we grew in size, scope and ambition. From July 2009 to May 2018, Ms. Homans served in multiple senior leadership positions at Genentech, including Vice President, U.S. Sales and Marketing Leader for Breast Cancer, Vice President, U.S. Sales and Marketing Leader for Xolair, Vice President, Global Regulatory Operations Leader and Vice President, Global Product Strategy, HER2 Franchise. From May 2004 through November 2007, Ms. Homans served as Executive Director, Project Leadership and Portfolio Management at Jazz Pharmaceuticals, Inc. Ms. Homans received an MBA from Columbia University in the City of New York and a B.A. in German and Economics from Bates University.